BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 33030198)

  • 1. Structure-based drug repurposing to inhibit the DNA gyrase of Mycobacterium tuberculosis.
    Gl B; Rajput R; Gupta M; Dahiya P; Thakur JK; Bhatnagar R; Grover A
    Biochem J; 2020 Nov; 477(21):4167-4190. PubMed ID: 33030198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and antitubercular activity of 4-alkoxy-triazoloquinolones able to inhibit the M. tuberculosis DNA gyrase.
    Carta A; Bua A; Corona P; Piras S; Briguglio I; Molicotti P; Zanetti S; Laurini E; Aulic S; Fermeglia M; Pricl S
    Eur J Med Chem; 2019 Jan; 161():399-415. PubMed ID: 30384044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In silico designing of domain B selective gyrase inhibitors for effective treatment of resistant tuberculosis.
    Kashyap A; Singh PK; Silakari O
    Tuberculosis (Edinb); 2018 Sep; 112():83-88. PubMed ID: 30205973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycobacterium Tuberculosis (MTB) GyrB inhibitors: An attractive approach for developing novel drugs against TB.
    Chaudhari K; Surana S; Jain P; Patel HM
    Eur J Med Chem; 2016 Nov; 124():160-185. PubMed ID: 27569197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel anti-tubercular and antibacterial based benzosuberone-thiazole moieties: Synthesis, molecular docking analysis, DNA gyrase supercoiling and ATPase activity.
    Omar MA; Masaret GS; Abbas EMH; Abdel-Aziz MM; Harras MF; Farghaly TA
    Bioorg Chem; 2020 Nov; 104():104316. PubMed ID: 33022549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benzothiazinone-piperazine derivatives as efficient Mycobacterium tuberculosis DNA gyrase inhibitors.
    Chandran M; Renuka J; Sridevi JP; Pedgaonkar GS; Asmitha V; Yogeeswari P; Sriram D
    Int J Mycobacteriol; 2015 Jun; 4(2):104-15. PubMed ID: 26972878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring the gyrase ATPase domain for tailoring newer anti-tubercular drugs: hit to lead optimization of a novel class of thiazole inhibitors.
    Jeankumar VU; Kotagiri S; Janupally R; Suryadevara P; Sridevi JP; Medishetti R; Kulkarni P; Yogeeswari P; Sriram D
    Bioorg Med Chem; 2015 Feb; 23(3):588-601. PubMed ID: 25541204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, biological evaluation of substituted benzofurans as DNA gyraseB inhibitors of Mycobacterium tuberculosis.
    Renuka J; Reddy KI; Srihari K; Jeankumar VU; Shravan M; Sridevi JP; Yogeeswari P; Babu KS; Sriram D
    Bioorg Med Chem; 2014 Sep; 22(17):4924-34. PubMed ID: 25129171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assays, surrogates, and alternative technologies for a TB lead identification program targeting DNA gyrase ATPase.
    Humnabadkar V; Madhavapeddi P; Basavarajappa H; Sheikh MG; Rane R; Basu R; Verma P; Sundaram A; Mukherjee K; de Sousa SM
    J Biomol Screen; 2015 Feb; 20(2):265-74. PubMed ID: 25300873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enabling the (3 + 2) cycloaddition reaction in assembling newer anti-tubercular lead acting through the inhibition of the gyrase ATPase domain: lead optimization and structure activity profiling.
    Jeankumar VU; Reshma RS; Janupally R; Saxena S; Sridevi JP; Medapi B; Kulkarni P; Yogeeswari P; Sriram D
    Org Biomol Chem; 2015 Feb; 13(8):2423-31. PubMed ID: 25569565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 4-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation.
    Medapi B; Suryadevara P; Renuka J; Sridevi JP; Yogeeswari P; Sriram D
    Eur J Med Chem; 2015 Oct; 103():1-16. PubMed ID: 26318054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thiazole-aminopiperidine hybrid analogues: design and synthesis of novel Mycobacterium tuberculosis GyrB inhibitors.
    Jeankumar VU; Renuka J; Santosh P; Soni V; Sridevi JP; Suryadevara P; Yogeeswari P; Sriram D
    Eur J Med Chem; 2013; 70():143-53. PubMed ID: 24148991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Potent DNA Gyrase Inhibitors Active against
    Pakamwong B; Thongdee P; Kamsri B; Phusi N; Kamsri P; Punkvang A; Ketrat S; Saparpakorn P; Hannongbua S; Ariyachaokun K; Suttisintong K; Sureram S; Kittakoop P; Hongmanee P; Santanirand P; Spencer J; Mulholland AJ; Pungpo P
    J Chem Inf Model; 2022 Apr; 62(7):1680-1690. PubMed ID: 35347987
    [No Abstract]   [Full Text] [Related]  

  • 14. Identification of novel gyrase B inhibitors as potential anti-TB drugs: homology modelling, hybrid virtual screening and molecular dynamics simulations.
    Maharaj Y; Soliman ME
    Chem Biol Drug Des; 2013 Aug; 82(2):205-15. PubMed ID: 23614896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel thiomorpholine tethered isatin hydrazones as potential inhibitors of resistant Mycobacterium tuberculosis.
    Karunanidhi S; Chandrasekaran B; Karpoormath R; Patel HM; Kayamba F; Merugu SR; Kumar V; Dhawan S; Kushwaha B; Mahlalela MC
    Bioorg Chem; 2021 Oct; 115():105133. PubMed ID: 34329993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In silico study directed towards identification of the key structural features of GyrB inhibitors targeting MTB DNA gyrase: HQSAR, CoMSIA and molecular dynamics simulations.
    Kamsri P; Punkvang A; Hannongbua S; Suttisintong K; Kittakoop P; Spencer J; Mulholland AJ; Pungpo P
    SAR QSAR Environ Res; 2019 Nov; 30(11):775-800. PubMed ID: 31607177
    [No Abstract]   [Full Text] [Related]  

  • 17. Chemical classes targeting energy supplying GyrB domain of Mycobacterium tuberculosis.
    Kashyap A; Singh PK; Silakari O
    Tuberculosis (Edinb); 2018 Dec; 113():43-54. PubMed ID: 30514513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of gyrase B as a drug target in Mycobacterium tuberculosis.
    Chopra S; Matsuyama K; Tran T; Malerich JP; Wan B; Franzblau SG; Lun S; Guo H; Maiga MC; Bishai WR; Madrid PB
    J Antimicrob Chemother; 2012 Feb; 67(2):415-21. PubMed ID: 22052686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycobacterium tuberculosis DNA gyrase as a target for drug discovery.
    Mdluli K; Ma Z
    Infect Disord Drug Targets; 2007 Jun; 7(2):159-68. PubMed ID: 17970226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An efficient synthesis and biological screening of benzofuran and benzo[d]isothiazole derivatives for Mycobacterium tuberculosis DNA GyrB inhibition.
    Reddy KI; Srihari K; Renuka J; Sree KS; Chuppala A; Jeankumar VU; Sridevi JP; Babu KS; Yogeeswari P; Sriram D
    Bioorg Med Chem; 2014 Dec; 22(23):6552-6563. PubMed ID: 25456076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.